Samsung Biologics
Samsung Biologics Co., Ltd. is a leading global contract development and manufacturing organization headquartered in South Korea that provides comprehensive biopharmaceutical production services. The company operates as the specialized biopharmaceutical arm of Samsung Group, offering end-to-end manufacturing solutions ranging from early cell line development to large-scale commercial production. Its principal service offerings include the contract manufacturing of monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and recombinant vaccines for global clients. Samsung Biologics' main revenue drivers stem from long-term manufacturing service agreements and partnership contracts executed with major international pharmaceutical and biotechnology corporations. As an industry leader in biopharmaceutical contract manufacturing, the company holds a dominant market position within the global biopharmaceutical manufacturing and healthcare sector, supporting innovative therapies worldwide. Headquartered in Songdo, Incheon, South Korea, Samsung Biologics is publicly listed and traded with common shares on the Korea Exchange.
26 of the funds FundTelligence covers report a position in Samsung Biologics.
- Legal name
- Samsung Biologics Co Ltd
- Sector
- Health Care
- Country
- South Korea
- Funds holding it
- 26
Funds holding Samsung Biologics
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 1.31 % (full portfolio disclosed, October 2026)
- Handelsbanken Global Bærekraft — Handelsbanken · 0.72 % (full portfolio disclosed, October 2026)
- Nordea Emerging Markets Sustainable Enhanced — Nordea Funds · 0.54 % (full portfolio disclosed, September 2026)
- Handelsbanken Vekstmarked Tema — Handelsbanken · 0.52 % (full portfolio disclosed, September 2026)
- Danske Invest Emerging Markets Sustainable Future — Danske Invest · 0.51 % (full portfolio disclosed, September 2026)
- Danske Invest Global Emerging Markets — Danske Invest · 0.49 % (full portfolio disclosed, September 2026)
- SEB Emerging Marketsfond — SEB · 0.37 % (full portfolio disclosed, June 2026)
- Danske Invest Global Emerging Markets Index Restricted — Danske Invest · 0.36 % (full portfolio disclosed, July 2026)
Showing the 8 largest of 26 funds holding it.